Mizuho lowered the firm’s price target on CVS Health (CVS) to $66 from $73 and keeps an Outperform rating on the shares. The firm cut estimates following last week’s preannouncement. The analyst believes the company’s medical loss ratio trends are likely to improve in 2025 due to start payments, but expects the MLR to remain elevated from 2023 baselines.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CVS:
- CVS Health price target lowered to $75 from $82 at Barclays
- Ex-Dividend Date Nearing for These 10 Stocks – Week of October 21, 2024
- UPS among dividend stocks with yield of 4%-plus, Barron’s says
- Netflix reports Q3 beat, CVS CEO Lynch steps down: Morning Buzz
- CVS Health falls -9.2%
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
